Hello, welcome to the TransCode Therapeutics, Inc. annual meeting of shareholders. I am Philippe Calais, the company's Chief Executive Officer and Chairman of the Board. We will be conducting the formal business of the meeting, notice of which was sent to all shareholders of record as of the close of business on May 28th, 2026. The meeting is now called to order. As I have been authorized by the Board of Directors, I hereby appoint Jenna Bentley as the Inspector of Election for this annual meeting. The Inspector of Election has now signed an oath of office. The affidavit of mailing and the oath of Inspector of Election will be filed with the minutes of this meeting. Although the annual meeting of shareholders was scheduled to be held this morning at 9:30 A.M., the Inspector of Election advises that a quorum is present at the meeting in person or by proxy, the meeting is hereby adjourned. As the presiding officer of the annual meeting, I have determined that it is in the best interest of the company and the shareholders to adjourn the meeting pursuant to the amended and restated bylaws of the meeting. Pursuant to Nasdaq Listing Rule 5110, Nasdaq must complete its review of and approve the company's initial listing application prior to the approval of Proposal 1 by the company stockholders. Nasdaq has not yet completed its review of the company's initial listing application. The adjournment of the annual meeting is to allow additional time for Nasdaq to complete its review. Based on the closing price of the company's common stock on July 1st, 2026, and other relevant factors, the company believes that it currently meets all initial listing criteria under the equity standard for the Nasdaq Capital Market and expects to obtain approval on this basis. Therefore, in accordance with the company's bylaws, this annual meeting is adjourned until July 20, 2026, at 9:30 A.M. Eastern Time, to be held virtually at www.virtualshareholdermeeting.com/rnaz2026. We anticipate receipt of Nasdaq's approval of our new listing application by that time. All stockholders of record as of the close of business on May 28th, 2026, the record date for this annual meeting, are still entitled to vote at the reconvened meeting. Shareholders who have already voted and who do not wish to change their vote need take no further action. Their votes will be included in the final tally. We look forward to your participation when the meeting is reconvened. Thank you. This now concludes the meeting. Thank you for joining, and have a pleasant day.